Opinions

Peter Arender, CFA Axcan Pharmaceuticals AXP-T BUY Nov 11, 2003

Has a very good ROE. Efficient balance sheet structure. Continuing to grow their earnings. Valuation is reasonable.

Peter Arender, CFA

Unknown

Unlock Rating

$17.400

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

STRONG BUY

Products selling very well. Sales force based in US

DON'T BUY

Had a nice run. May be a bit high now.

BUY

A good long term hold. They focus on their earnings. Well managed.

DON'T BUY

Its OK earnings wise. They are trying to make a hostile take over which looks expensive. Core business is OK.

TOP PICK

The entire US financial sector is attractive. Their brokerage sector is growing rapidly. Expects travel business will pick up.

TOP PICK

Last news was that R&D spending would be higher than the street anticipated. Launching a product that could be a $200 million product.

TOP PICK

A very focused (gastro intestinal) pharmaceutical company and as a result, it is very profitable. You pretty well get a free call option on a potentially block-buster drug called Itax. Huge market in North America.

TOP PICK

Part pharmaceutical and part drug development. Very profitable. Strong balance sheet and lots of cash flow. Generates about US$1.50 free cash flow every year. In a very stable gastro-intestinal market. They're also in-licence some drugs which gives them some pretty good upside. Trading at about US$14 with $1 a share free cash on the balance sheet.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Peter Arender, CFA Axcan Pharmaceuticals AXP-T BUY Nov 11, 2003

You might be interested:

Axcan Pharmaceuticals(AXP-T)

Axcan Pharmaceuticals(AXP-T)

Axcan Pharmaceuticals(AXP-T)

Axcan Pharmaceuticals(AXP-T)

Axcan Pharmaceuticals(AXP-T)

Axcan Pharmaceuticals(AXP-T)

Axcan Pharmaceuticals(AXP-T)

Axcan Pharmaceuticals(AXP-T)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Stockchase Insights

Rebecca Teltscher

Andrey Omelchak

The Panic-Proof Portfolio (Stockchase Research)

The Monthly Gems by Allan Tong